Drug Profile


Alternative Names: TAK-875

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Takeda
  • Class Antihyperglycaemics; Benzofurans; Small molecules; Sulfones
  • Mechanism of Action FFAR1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 27 Dec 2013 Discontinued - Phase-III for Type-2 diabetes mellitus (combination therapy) in USA, Argentina, Australia, Brazil, Bulgaria, Canada, Colombia, Croatia, the Czech Republic, Estonia, France, Germany, Hong Kong, Hungary, Israel, Italy, Latvia, Lithuania, Malaysia, Mexico, New Zealand, Peru, the Philippines, Poland, Romania, Russia, Slovakia, South Africa, South Korea, Thailand, Ukraine and United Kingdom (PO)
  • 27 Dec 2013 Discontinued - Phase-III for Type-2 diabetes mellitus (monotherapy) in Argentina, Bulgaria, Hungary, Guatemala, Mexico, Slovakia, Ukraine and USA (PO)
  • 27 Dec 2013 Discontinued - Phase-III for Type-2 diabetes mellitus in Australia, China, Japan, New Zealand, South Korea and Taiwan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top